2020 SIDP Annual Meeting (BCIDP+ACPE Credit): Early Antifungals in the ICU: Untangling the Unnecessarily Complex; Antibiotic De-escalation: Preventing Resistance or Futile Existence?

This includes two activities from the 2020 SIDP Annual Meeting that are available on-demand for home-study BCIDP+ACPE Credit.

A product of the Society of Infectious Diseases Pharmacists Education Center (SIDPEC) 

 
 View more SIDPEC Activities
 

NOTE: If you attended these live CE activities held on November 14, 2020 at the SIDP Annual Meeting AND received CE credit (i.e. a pharmacist CE statement with ACPE Universal Activity Number 0221-9999-20-518-L01-P or 0221-9999-20-520-L01-P), you are NOT eligible to also receive CE credit for these home-study activities.

1. 

Early Antifungals in the ICU: Untangling the Unnecessarily Complex

Description

This activity will focus on antifungals and discuss evidence regarding their use on invasive candidiasis in critically ill patients. Non-culture diagnostic techniques will also be evaluated.

This is a featured CE activity on the Society of Infectious Diseases Pharmacists Education Center (SIDPEC) website. SIDPEC is the educational hub of the Society of Infectious Diseases Pharmacists (SIDP). The SIDPEC portal provides educational activities on infectious disease pharmacotherapy for clinical pharmacists, health‐systems pharmacists, community pharmacists, and other allied‐health disciplines.

Learning Objectives

The target audience for this activity is pharmacists. At the completion of this activity, the participant will be able to:

  • Describe the epidemiology of invasive candidiasis in critically ill patients.
  • Discuss recent evidence regarding the use of early antifungals in critically ill patients.
  • Evaluate evidence regarding non-culture diagnostic techniques for invasive candidiasis.
  • Propose reasonable indications for the use of early antifungals in critically ill patients.
     

Faculty

Gregory Eschenauer, PharmD
University of Michigan College of Pharmacy
 

Accreditation

Release Date: November 14, 2020
Expiration Date: November 14, 2023
BCIDP Expiration Date: November 14, 2021

Pharmacists

ACPE LogoThis activity is jointly provided by ProCE, LLC and the Society of Infectious Diseases Pharmacists. ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-20-518-H01-P has been assigned to this home-study knowledge-based activity. This activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Statements of completion will be issued online at www.ProCE.com upon completion of the evaluation and post-test with a score of 70% or higher. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.

Disclosure

It is the policy of ProCE, LLC to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed in this activity. Gregory Eschenauer is a consultant for Wolters Kluwer (Lexi-Comp).

2. 

Antibiotic De-escalation: Preventing Resistance or Futile Existence?

Description

Expert faculty will debate the pros and cons of Antibiotic De-escalation. Primary literature and guidelines recommendations regarding de-escalation and antibiotic resistance will frame the basis for this discussion as best practices are identified.

This is a featured CE activity on the Society of Infectious Diseases Pharmacists Education Center (SIDPEC) website. SIDPEC is the educational hub of the Society of Infectious Diseases Pharmacists (SIDP). The SIDPEC portal provides educational activities on infectious disease pharmacotherapy for clinical pharmacists, health‐systems pharmacists, community pharmacists, and other allied‐health disciplines.

Learning Objectives

The target audience for this activity is pharmacists. At the completion of this activity, the participant will be able to:

  • Review the primary literature about de-escalation and antibiotic resistance.
  • Compare primary literature and guideline recommendation regarding de-escalation.
  • Identify best practices related to antibiotic de-escalation.

Faculty

Keriann Bennett PharmD, BCPS, BCIDP
Antimicrobial Stewardship Pharmacist, Gritman Medical Center
Pharmacist II, St. Joseph Regional Medical Center

John M. Allen, PharmD, BCPS, BCCCP, FCCM, FCCP
Clinical Assistant Professor
University of Florida College of Pharmacy

Accreditation

Release Date: November 14, 2020
Expiration Date: November 14, 2023
BCIDP Expiration Date: November 14, 2021

Pharmacists

ACPE LogoThis activity is jointly provided by ProCE, LLC and the Society of Infectious Diseases Pharmacists. ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-20-520-H01-P has been assigned to this home-study knowledge-based activity. This activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Statements of completion will be issued online at www.ProCE.com upon completion of the evaluation and post-test with a score of 70% or higher. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.

Disclosure

It is the policy of ProCE, LLC to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed in this activity. Keriann Bennett and John Allen have no relevant commercial or financial relationships to disclose.

BCIDP

The Society of Infectious Diseases Pharmacists (SIDP) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of board certified infectious diseases pharmacist (BCIDP) credit. A BCIDP statement of credit will be issued online upon successful completion of a post-test and online evaluation. The post-test must be successfully completed in only one attempt. No partial credit will be given. BCIDP accreditation begins 11/14/2020 for these activities and is available for one year from this date.

Recertification Criteria for Infectious Diseases Pharmacy: BCIDP recertifying via continuing education are required to earn 100 hours of continuing education credit provided by the joint program offered by the Society of Infectious Diseases Pharmacists (SIDP), American College of Clinical Pharmacy (ACCP) and/or the American Society of Health-System Pharmacists (ASHP). Infectious Diseases Pharmacy Specialty Recertification Courses offered by any of the approved providers may only be completed for recertification credit up to two times, in nonconsecutive years, during the 7-year recertification cycle. Candidates should note that there are expiration dates associated with earning BPS recertification credit. BPS will only award recertification credit for modules based on the completion and submission date of the post-test assessment. For example, a module completed and submitted on October 20 of a particular year will only be credited for that year, even if the due date of the post-test is in January of the following year. View all recertification criteria on the BPS website at https://www.bpsweb.org/recertification/recertification-by-continuing-education

Funding

No external support has been received for this activity.

The material presented in this CE activity does not reflect the views of ProCE, LLC or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.